Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More
DR. REDDYS LAB | CIPLA | DR. REDDYS LAB/ CIPLA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.9 | 29.4 | 118.6% | View Chart |
P/BV | x | 4.8 | 4.2 | 114.9% | View Chart |
Dividend Yield | % | 0.6 | 0.5 | 113.0% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. REDDYS LAB Mar-20 |
CIPLA Mar-20 |
DR. REDDYS LAB/ CIPLA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,363 | 586 | 574.4% | |
Low | Rs | 2,352 | 357 | 659.2% | |
Sales per share (Unadj.) | Rs | 1,054.2 | 207.0 | 509.2% | |
Earnings per share (Unadj.) | Rs | 121.9 | 18.6 | 655.6% | |
Cash flow per share (Unadj.) | Rs | 190.2 | 33.2 | 573.6% | |
Dividends per share (Unadj.) | Rs | 25.00 | 4.00 | 625.0% | |
Dividend yield (eoy) | % | 0.9 | 0.8 | 103.1% | |
Book value per share (Unadj.) | Rs | 938.7 | 195.5 | 480.2% | |
Shares outstanding (eoy) | m | 166.17 | 806.35 | 20.6% | |
Bonus/Rights/Conversions | ESOP | ESOS | - | ||
Price / Sales ratio | x | 2.7 | 2.3 | 119.1% | |
Avg P/E ratio | x | 23.4 | 25.3 | 92.5% | |
P/CF ratio (eoy) | x | 15.0 | 14.2 | 105.7% | |
Price / Book Value ratio | x | 3.0 | 2.4 | 126.3% | |
Dividend payout | % | 20.5 | 21.5 | 95.3% | |
Avg Mkt Cap | Rs m | 474,831 | 379,912 | 125.0% | |
No. of employees | `000 | 21.7 | 25.8 | 83.8% | |
Total wages/salary | Rs m | 33,802 | 30,270 | 111.7% | |
Avg. sales/employee | Rs Th | 8,091.0 | 6,459.6 | 125.3% | |
Avg. wages/employee | Rs Th | 1,561.3 | 1,171.2 | 133.3% | |
Avg. net profit/employee | Rs Th | 935.8 | 580.2 | 161.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 175,170 | 166,949 | 104.9% | |
Other income | Rs m | 6,206 | 3,442 | 180.3% | |
Total revenues | Rs m | 181,376 | 170,391 | 106.4% | |
Gross profit | Rs m | 24,421 | 32,060 | 76.2% | |
Depreciation | Rs m | 11,348 | 11,747 | 96.6% | |
Interest | Rs m | 983 | 1,974 | 49.8% | |
Profit before tax | Rs m | 18,296 | 21,782 | 84.0% | |
Minority Interest | Rs m | 0 | -475 | 0.0% | |
Prior Period Items | Rs m | 561 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -1,403 | 6,312 | -22.2% | |
Profit after tax | Rs m | 20,260 | 14,995 | 135.1% | |
Gross profit margin | % | 13.9 | 19.2 | 72.6% | |
Effective tax rate | % | -7.7 | 29.0 | -26.5% | |
Net profit margin | % | 11.6 | 9.0 | 128.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 125,991 | 117,038 | 107.6% | |
Current liabilities | Rs m | 72,141 | 43,931 | 164.2% | |
Net working cap to sales | % | 30.7 | 43.8 | 70.2% | |
Current ratio | x | 1.7 | 2.7 | 65.6% | |
Inventory Days | Days | 73 | 96 | 76.3% | |
Debtors Days | Days | 105 | 85 | 123.1% | |
Net fixed assets | Rs m | 83,854 | 107,424 | 78.1% | |
Share capital | Rs m | 831 | 1,613 | 51.5% | |
"Free" reserves | Rs m | 155,157 | 156,018 | 99.4% | |
Net worth | Rs m | 155,988 | 157,630 | 99.0% | |
Long term debt | Rs m | 1,304 | 23,693 | 5.5% | |
Total assets | Rs m | 232,253 | 236,626 | 98.2% | |
Interest coverage | x | 19.6 | 12.0 | 162.9% | |
Debt to equity ratio | x | 0 | 0.2 | 5.6% | |
Sales to assets ratio | x | 0.8 | 0.7 | 106.9% | |
Return on assets | % | 9.1 | 7.2 | 127.5% | |
Return on equity | % | 13.0 | 9.5 | 136.5% | |
Return on capital | % | 12.6 | 12.8 | 98.2% | |
Exports to sales | % | 0 | 33.0 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 55,175 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 84,193 | 56,036 | 150.2% | |
Fx outflow | Rs m | 39,616 | 6,764 | 585.7% | |
Net fx | Rs m | 44,577 | 49,272 | 90.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 29,841 | 30,685 | 97.3% | |
From Investments | Rs m | -4,923 | 1,040 | -473.2% | |
From Financial Activity | Rs m | -25,159 | -29,488 | 85.3% | |
Net Cashflow | Rs m | -266 | 2,340 | -11.4% |
Indian Promoters | % | 25.5 | 16.0 | 159.4% | |
Foreign collaborators | % | 0.0 | 20.8 | - | |
Indian inst/Mut Fund | % | 5.4 | 12.2 | 44.3% | |
FIIs | % | 35.3 | 23.7 | 148.9% | |
ADR/GDR | % | 18.5 | 1.1 | 1,681.8% | |
Free float | % | 15.3 | 26.2 | 58.4% | |
Shareholders | 75,885 | 161,166 | 47.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: AJANTA PHARMA GLENMARK PHARMA AUROBINDO PHARMA STRIDES PHARMA SCIENCE FDC
Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets ended their day on a flat note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 35 points (up 0.1%).
For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
This could be the biggest wealth creator of the decade.
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More